Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Audio content above is prompted by the following:
Prolaris Genomic Testing: Clinical Implications for Prostate Cancer Management
Key Distinguishing Features
Prolaris represents a significant advancement in prostate cancer genomic biomarker platforms, offering unique capabilities in:
- Quantitative assessment of cancer aggressiveness through cell-cycle progression gene expression analysis
- Precise prediction of absolute benefit from androgen deprivation therapy (ADT) when combined with radiation therapy
- Providing actionable clinical information that goes beyond traditional risk stratification methods
Clinical Utility and Practice-Changing Insights
Most Impactful Clinical Scenarios
- Patients with intermediate-risk prostate cancer considering radiation therapy
- Patients with uncertainties about additional treatment necessities
- Cases where traditional risk stratification methods provide insufficient guidance
Evidence-Based Recommendations
- Offers a more nuanced approach to treatment decision-making
- Enables personalized treatment strategies by accurately quantifying individual cancer progression risk
- Supports more targeted use of ADT, potentially reducing overtreatment
Emerging Considerations
- Continued refinement of genomic testing methodologies
- Increasing integration of molecular insights into treatment algorithms
- Potential for more precise, individualized treatment planning
Clinical Preparation
Physicians should:
- Stay informed about latest genomic testing advancements
- Understand the specific molecular mechanisms underlying Prolaris testing
- Integrate genomic insights with traditional clinical parameters
- Maintain a patient-centered approach to treatment decision-making
Recommended Action
Incorporate Prolaris testing as a complementary tool in prostate cancer management, particularly for patients in intermediate-risk categories where treatment decisions require additional precision.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
